Beyond the needle: Building the future of intratumoral oncology – Basel

Intratumoral oncology is emerging as a powerful complement to systemic therapies in cancer care. By delivering treatment directly into tumors, these approaches enable precise, localized activity where disease is concentrated, strengthen local control, and open new opportunities for combination with radiation, chemotherapy, and immunotherapy. Advances in this space include local immune activators, oncolytic viruses, radio-enhancers/radiosensitizers, and locally delivered cell therapies.

Join Johnson & Johnson’s Interventional Oncology (INTO) and Oncology teams on October 23 in Basel for an engaging dialogue with senior leaders and experts to explore how intratumoral therapies are shaping the future of oncology.

The discussion during the event will focus on key topics including:

• J&J’s external innovation model and how it drives partnering
• Interventional Oncology and Oncology strategies and sourcing priorities
• Partnership opportunities to advance intratumoral and systemic therapies into and through the clinic
• Networking with entrepreneurs, start-ups, biotech leaders, and investors

During this event, organized in collaboration with BaseLaunch, you will also learn how Johnson & Johnson integrates Innovative Medicine and MedTech expertise to develop therapies designed to augment the mainstays of cancer care with complementary and synergistic locally acting drugs.

1:1 Meetings
Innovators in this space are invited to apply for a 1:1 meeting with the J&J team by October 7. Discussions may cover potential collaboration, incubation, or investment opportunities across J&J Oncology’s priority disease areas, platforms, and enabling technologies.
Apply Now